Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-STAT5A mRNAs with seed-region complementarity refers to the collection of messenger RNA transcripts that are unintentionally downregulated by RNA interference (RNAi) tools, such as siRNAs or shRNAs, designed to target the STAT5A gene. This phenomenon occurs because the 'seed region' of the small RNA guide strand (typically nucleotides 2-8) can recognize and bind to partially complementary sequences in the 3' untranslated regions (UTRs) of many other genes, mimicking the natural regulatory mechanism of microRNAs (Birmingham et al., 2006; Jackson et al., 2003). In the case of STAT5A, a transcription factor critical for hematopoietic signaling and oncogenesis, such off-target effects can lead to significant cellular toxicity or misleading phenotypic observations in research and clinical development. STAT5A itself is a member of the Signal Transducer and Activator of Transcription family and plays a pivotal role in cytokine signaling, cell growth, and survival. Dysregulation of STAT5A is associated with various leukemias and solid tumors, making it an attractive therapeutic target; however, the development of RNAi-based inhibitors is complicated by these potential seed-region mediated off-target effects. Consequently, researchers focus on identifying and mitigating these 'Non-STAT5A' interactions using chemical modifications or advanced bioinformatics to ensure that the therapeutic effect is solely due to the inhibition of the intended STAT5A protein.
Unintended gene silencing via a microRNA-like mechanism where the seed region (nucleotides 2-7 or 2-8) of a STAT5A-targeting siRNA or shRNA binds to complementary sequences in the 3' untranslated regions (UTRs) of non-target mRNAs, leading to their degradation or translational repression.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-STAT5A mRNAs with seed-region complementarity.